Drug Approval | July 10, 2023
Astellas receives FDA priority review for Zolbetuximab biologics license application
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Collaboration to provide hospitals with a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy
Rare childhood cancer subtype, Ph+ ALL, is found in 3-4% of pediatric cases and 25% of adult cases
The launch of HULIO in the United States is an important milestone for Biocon Biologics
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
The company is already marketing the 4 mg and 10 mg strengths
Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement
The product will be produced at the Eugia Pharma Specialities, Unit-I, Medchal, Malkajgiri District, Telangana, India
This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio
Subscribe To Our Newsletter & Stay Updated
